INTRODUCTION
Colorectal cancer (CRC) is a common and deadly malignancy in both the US and Europe, with an estimated total of 258,000 and 136,000 new cases per year, respectively [1, 2] . However, overall survival (OS) of patients with advanced CRC has been improved by the combination of traditional anti-proliferative agents with newer targeted molecules, which inhibit signal transduction pathways [3, 4] . A current challenge concerns both the selection of patients with a poor prognosis to be directed towards the most effective treatment, and the identi cation of reliable predictive markers of response. Circulating tumor cells (CTCs) have been recognized in patients carrying di erent cancer types [5, 6] . e CTC count was reported to correlate with disease stage, and to predict OS in patients with advanced CRC [7] [8] [9] . Moreover, low CTC levels before and during chemotherapy were associated with a better clinical response [10] . However, the prognostic role of CTCs in patients with CRC has not been de nitely established so far. We therefore designed a cohort study aimed to evaluate the prognostic role of CTC count in CRC patients.
PATIENTS AND METHODS

Patients
Consecutive CRC patients observed from October 2007 to September 2009 in a single center were enrolled. Performance status (PS) was classi ed according to the Eastern Cooperative Oncology Group (ECOG) score. CTC count was performed on blood samples collected before chemotherapy (T0) and 1 month a er start of therapy (T1). Patients provided their written informed consent to participate in this study. e study design was approved by the Ethical Committee of the Sant' Andrea Hospital (Prot. C.E. 1242/2013). 
CTC detection
Brie y, 7.5 mL of peripheral blood was collected from each patient for CTC evaluation. Peripheral Blood Mononuclear Cells (PBMCs) were isolated using Ficoll-Paque (Miltenyi Biotec, Bergisch Gladbach, Germany) density centrifugation at 2,400 rpm for 30 min and re-suspended for magnetic labeling in 300 µL of MACS® separation buffer (Miltenyi Biotec). According to the manufacturer's instructions, PBMCs were incubated for 30 minutes at 4°C with 100 µL of CD326 (EpCAM) MicroBeads (Miltenyi Biotec). en, MS separation columns (Miltenyi Biotec) had been equilibrated with 0.5 ml of MACS® separation bu er, and the micro-beads labeled cells were subjected to a magnetic eld through the column passage. us, the column was removed from the magnetic separator and placed on a suitable collection tube for the recovery of sample enriched of CD326+ cells (Fig.1 ). e sample with CD326+ cells were incubated with anti-CD326 PE and anti-CD45 FITC monoclonal antibodies (1:10 in MACS® separation bu er) for 15 min at 4°C (Fig. 1C ). Cells were then washed, centrifuged at 1,300 rpm for 6 min at 25°C and the pellet was re-suspended in 10 mL of cells solution and spotted on 8 wells diagnostic slides (Menzel-Glaser, Braunschweig, Germany), le to dry and xed with acetone for 8 min at -20°C. Nuclei were stained with DAPI (1 ng/mL, Sigma Chemicals, St Louis, MO). A er appropriate washing, cover slips were finally mounted with mowiol for observation. Cells were analyzed by conventional uorescence or by scanning in a series of 0.5 mm sequential optical sections with an ApoTome System (Zeiss, Oberkochen, Germany) connected with an Axiovert 200 inverted microscope (Zeiss). Image analysis was performed by the Axiovision so ware (Zeiss). Single optical sections were acquired by a CCD camera and image analysis was performed by the Axiovision so ware (Zeiss) [11] . e CTCs were identi ed as CD326+DAPI+CD45-cells. e CTC isolation technique was optimized by recovery experiments of serial dilutions (10 4 -10 1 /7.5 mL in healthy volunteer's blood) of cancer cell lines from the colon (HT29, Caco2). A threshold to de ne unfavorable CTC levels was de ned as ≥2/7.5 mL peripheral blood, because the conventional unfavorable cut-o ≥ 3 CTCs could negatively a ect the clinical utility of assay as a predictive marker in advanced stages CRC [12] . CTCs were not detected in 10 healthy volunteers, recruited as negative controls.
Statistical analysis
Data were compared by using the Chi-squared test and the Fisher's exact test, as appropriate. A logistic regression analysis was performed to assess the association between CTC count and clinical parameters. The analysis of OS, de ned as the time from baseline blood collection to death, and progression-free survival (PFS), de ned as the period from baseline blood collection until the detection of recurrent disease, were calculated with the Kaplan-Meier method and compared by using the log-rank test. Patients were censored at the last observation when disease progression or death did not occur. Multivariate Cox proportional-hazards regression was performed to analyze the e ect of all variables on OS, and only those factors signi cantly associated at univariate analysis were included. For all comparisons, a P value <0.05 was considered statistically signi cant. Statistical analysis was performed using the SPSS PASW Statistics ver.19.0.
RESULTS
Seventy-ve (M/F: 47/28; median age: 68, range 29-81 years) patients were enrolled in the study, including 54 patients (72%) with an early stage disease (I-III) and 21 (28%) with a metastatic disease (stage IV) (Table I) . A total of 55 tumors (73.3%) were located in the colon, and 20 (26.7%) in the rectum. Fortythree (79.6%) patients with stages II-III received adjuvant chemotherapy (79% uoropyrimidin plus oxaliplatin). None of the patients with stage IV disease underwent metastases resection before entering the chemotherapy protocol, and 52% received oxaliplatin-based chemotherapy. Overall, a positive baseline CTC (T0) count was detected in 21 (28%) patients. As shown in Table II , the prevalence of CTC positivity did not signi cantly di er according to age, gender, di erentiation and site of primary tumor or recurrence. CTCs (T0) were strongly associated with either disease stage (P = 0.001) and ECOG PS (P = 0.02). At the follow-up time point (T1), 11 (22.4%) out of 49 patients had ≥2 CTCs. ere was no di erence in CTC (T1) count irrespective of type of chemotherapy received (regimens with or without oxaliplatin), and site of tumor recurrence (hepatic vs. extrahepatic) (data not shown).
Cumulatively, the mean PFS and OS were 48.8 (CI: 41.8-55.8) and 55.5 (CI: 49.0-61.9) months, respectively. When patients were categorized according to the CTCs (T0), a positive status was associated with a reduction of both PFS Fig. 2) . At multivariate regression analysis, only the UICC stage was found to be an independent predictor of both PFS (p<0.001; HR: 19.41, 95% CI: 7.36-51.2) and OS (p<0.001; HR: 13.94, 95% CI: 5.62-34.62). However, a CTC positive count at T1 was found to be an independent predictive factor for reduced OS (P = 0.03; HR: 3.55, CI: 1.09−11.47), while CTC positive count at T0 showed a trend towards the signi cance (P = 0.09; HR: 1.97, CI: 0.89-4.37). isolated from other cells by using immune-magnetic techniques that recognize speci c surface markers such as EpCAM. We used the MACS® system, that is one of these accurate methods [13, 14] . e prevalence rate we detected in patients with CRC was consistent with data of previous studies, ranging from 29% to 36% [7, 8, 10] . To date, only few studies suggested the potential role of CTCs in predicting survival in CRC patients [8] [9] [10] . In the present study we found that a CTC positive status before chemotherapy is a signi cant factor associated with patients' survival. In detail, the OS in patients with CTC (T0) positive was near half as compared to that of patients with negative CTCs, with a HR of 1.97. In addition, CTC monitoring at follow-up is useful to further predict a reduced survival in those patients with a positive status, suggesting a more strict follow-up and/or a more aggressive cancer treatment. In detail, we observed that survival was signi cantly reduced in patients with CTCs positivity detected a er 1 month of chemotherapy. Our data are in keeping with the results of a recent metaanalysis showing that presence of CTCs in peripheral blood is associated with a lower OS as compared to those with a negative count (HR = 2.28, 95% CI: 1.55-3.38) [15] . In addition, it was found that CTC determination is more accurate than postchemotherapy CEA levels assessment in predicting relapse in these patients [16] . Based on the results of our study, it would appear clinically relevant to further investigate the predictive value of CTCs in localized (Stage I-II) CRC patients in whom data are still scanty [17] [18] [19] . Indeed, CTCs may be detected in 15−22% of these patients. For instance, chemotherapy is not routinely advisable for low-risk stage II colorectal cancer patients [20, 21] , despite the fact that a de nite risk of disease recurrence has been demonstrated also in these patients. In such a scenario, CTC assessment, along with other traditional prognostic factors, could allow a more accurate selection of patients deserving enhanced follow-up and/or an adjuvant treatment.
DISCUSSION
CONCLUSION
Our data support the prognostic role for CTC count in CRC patients. However, further studies aimed at con rming these ndings in the early stages of the disease are necessary.
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